Top 6 takeaways from Merck's R&D update
This article was originally published in Scrip
Executive Summary
Big pharma and large biotech companies once again are considering mega-mergers to increase market value, but Merck & Co chairman and CEO Kenneth Frazier says the company will grow via research and development innovation as well as smaller acquisitions rather than through consolidation, so its R&D strategy is increasingly important (scripintelligence.com, 30 April 2014).